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Case series
Do gynecologic oncology patients with severely diminished renal function
and urinary tract obstruction beneﬁt from ureteral stenting or percutaneous
nephrostomy?
Brooke Lianga, Sara S. Langea,1, L. Stewart Massada, Rebecca Dickb, Kathryn A. Millsa,
Andrea R. Hagemanna, Carolyn K. McCourta, Premal H. Thakera, Katherine C. Fuha,
David G. Mutcha, Matthew A. Powella, Lindsay M. Kurokia,⁎
a Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri, United States of America
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A R T I C L E I N F O
Keywords:
Urinary tract obstruction
Gynecologic oncology
Diuretic renal scintigraphy
Ureteral stent
Percutaneous nephrostomy tube
A B S T R A C T
Objective: To assess the renal outcomes of gynecologic oncology patients who present with hydronephrosis and
acute kidney injury (AKI), have< 20% renal function on diuretic renal scintigraphy, and undergo placement of a
ureteral stent or percutaneous nephrostomy (PCN) tube.
Methods: This is a single-institution case series of gynecologic oncology patients who underwent diuretic renal
scintigraphy from January 1, 2007, to June 1, 2017. Univariate and multivariate logistic analyses were used to
assess predictors of< 20% renal function. Recovery from AKI or elevated creatinine was reported for women
with<20% renal function who received a unilateral ureteral stent or PCN tube on the same side as their more
compromised kidney.
Results: Among 353 gynecologic oncology patients who underwent diuretic renal scintigraphy, 58 (16%) had
renal function<20%. Mean age was 59.6 years, 17% had preexisting chronic kidney disease, and 44% had a
diagnosis of cervical cancer. Renal atrophy on computed tomography scan (aOR 18.24, 95% CI 1.21–274.92)
predicted renal function<20%. Of 10 women with<20% renal function who received a stent or PCN tube, 7
recovered from AKI or elevated creatinine.
Conclusions: Gynecologic oncology patients with<20% renal function may recover from AKI after placement of
a stent or PCN tube, indicating that a diuretic renal scintigraphy cutoﬀ of< 20% renal function may be overly
conservative. Future studies are warranted to determine optimal renal function cutoﬀs for stent/PCN tube
placement in gynecologic oncology patients.
1. Introduction
Gynecologic oncology patients commonly experience urinary tract
obstruction due to tumor extension, metastatic growth, or radiation
therapy (Shingleton et al., 1969). Upon detecting such obstructions,
providers must decide whether or not to recommend placing a ureteral
stent or percutaneous nephrostomy (PCN) tube. Although such proce-
dures might prevent acute kidney injury (AKI) and improve overall
morbidity and mortality (Lienert et al., 2009; Patel et al., 2015), they
could be futile when kidney function is too impaired.
A valuable method for assessing kidney function is diuretic renal
scintigraphy. In contrast to ultrasound and other renal imaging, this
nuclear medicine imaging study assesses both ureteral obstruction and
renal function in a single test. Renal scintigraphy measures the speed of
radiotracer clearance through the urinary tract after diuretic adminis-
tration. Clearance is rapid in a non-obstructed system, but slow or en-
tirely stagnant in an obstructed system. A further advantage of renal
scintigraphy is that it can quantify diﬀerential excretion times of the
two kidneys and calculate the percent contribution of each kidney to
the patient's total renal function.
According to the urology literature, diuretic scintigraphy revealing
≥20% kidney function is the generally accepted threshold of kidney
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salvageability (Ganatra and Loughlin, 2005; Klaipetch et al., 2013;
KDIGO, 2012; Xu et al., 2017). If kidney function is less than this cutoﬀ,
placement of a ureteral stent or PCN tube is likely to be futile. However,
no studies have assessed the validity of this cutoﬀ in a gynecologic
oncology patient population. Given that such patients' cancer treatment
options (e.g., chemotherapy, immunotherapy, radiosensitizing agents)
may depend on renal function, it is important to determine whether the
20% cutoﬀ is appropriate in this population.
To address this question, we retrospectively analyzed a case series of
gynecologic oncology patients at our institution who presented with
hydronephrosis and AKI and underwent renal scintigraphy. Speciﬁcally,
our objective was to determine the rate of recovery from kidney injury
in patients who underwent ureteral stenting or PCN on the same side as
their more compromised kidney. Additionally, because diuretic renal
scintigraphy may not be available to all gynecologic oncologists, we
sought to describe clinicodemographic predictors of< 20% renal
function.
2. Methods
This was a single-institution retrospective case series of all gyne-
cologic oncology patients who underwent diuretic renal scintigraphy
between January 1, 2007, and June 1, 2017. Before study initiation, all
study procedures were reviewed and approved by the Washington
University Human Research Protection Oﬃce (Institutional Review
Board project # 201708045).
Patients were identiﬁed by querying the Barnes-Jewish Hospital
(BJH) Nuclear Medicine database for inpatient and outpatient diuretic
renal scintigraphy tests ordered within the Division of Gynecologic
Oncology. We included patients with cervical, endometrial, ovarian/
fallopian/peritoneal, vaginal, or vulvar cancer, as well as gestational
trophoblastic disease, and those with a cancer of unknown but assumed
gynecologic origin. If multiple diuretic renal scintigraphy tests were
performed during the same hospitalization or AKI work-up, only the
initial scan result was included in our analysis.
Diuretic renal scintigraphy was performed at our institution as fol-
lows: Patients were ﬁrst hydrated with 500ml of water orally and
500ml of normal saline infused intravenously over 30mins starting
15mins before the procedure. Next, they were intravenously adminis-
tered 7.5 mCi of Technetium Mertiatide (Tc-99m MAG3). Patients were
then asked to void, and 2–4mins of baseline data were acquired.
Twenty minutes after Tc-99m MAG3 administration, 40mg of the
diuretic furosemide was given intravenously over 1–2mins, and data
were acquired continuously for 20mins after furosemide administra-
tion.
AKI was deﬁned according to the Kidney Disease: Improving Global
Outcomes (KDIGO) criteria: serum creatinine increase by 0.3mg/dl in
48 h or by 1.5-fold in 7 days (KDIGO, 2012). Other elevations in serum
creatinine noted by clinicians that did not meet criteria were captured
and classiﬁed as “elevated creatinine”. Development of chronic kidney
disease (CKD) after AKI was deﬁned according to the KDIGO criteria:
presence of kidney damage or decreased glomerular ﬁltration rate <
60mls/min/1.73 m2 for 3 or more months (KDIGO, 2012). Failure to
salvage was deﬁned as a serum creatinine that did not return to within
25% of baseline by 3months after the procedure or death due to AKI
(Pannu et al., 2013).
We extracted demographic and clinicopathologic data including age
at diuretic renal scintigraphy, race, insurance, tobacco use, comorbid-
ities, primary cancer type, cancer stage, indication for diuretic renal
scintigraphy, and documented renal ﬁndings on computed tomography
(CT) scan (e.g., renal atrophy, cortical thinning, or hydronephrosis/
hydroureter) as reported by the BJH radiology department. Renal in-
terventions (e.g., ureteral stents and/or PCN tubes) and outcomes were
captured.
Standard descriptive statistics including median and interquartile
range for continuous variables, and count and percentage for
categorical variables, were used to summarize demographic/clin-
icopathologic characteristics, stent/PCN placement, and renal out-
comes. Mann-Whitney U or Student's t-test were used to analyze sig-
niﬁcance in continuous variables, and Fisher's Exact or χ2 tests were
used for categorical variables.
Univariate and multivariate logistic regression models were used to
assess predictors of< 20% renal function. The predictors that were
signiﬁcantly diﬀerent between groups in bivariate analysis with a sig-
niﬁcance level of 0.05 (renal atrophy on CT scan, prior pelvic/ab-
dominal radiation, and AKI satisfying KDIGO criteria) were controlled
for in a logistic regression model. Stata 15 (Stata Statistical Software,
Release 15, College Station, TX) was used for all analyses.
3. Results
Our query of the nuclear medicine database yielded 420 diuretic
renal scintigraphy tests ordered by the gynecologic oncology division
between January 1, 2007, and June 1, 2017. 353 diuretic renal scin-
tigraphy tests remained after patients with benign diagnoses were ex-
cluded and extra scans ordered within the same hospitalization or AKI
work-up were removed. Of the 353 test results, 58 (16%) revealed<
20% renal function. Of the patients with< 20% renal function, mean
age was 57.2, and most were insured, non-obese, white patients with
advanced or recurrent gynecologic malignancy, most often cervical
cancer (Table 1).
Among women with<20% renal function, indications for diuretic
renal scintigraphy were mainly the provider's suspicion for hydrone-
phrosis/hydroureter (84%) and/or elevated creatinine or suspected AKI
(55%). Providers ordered multiple imaging studies in tandem with
diuretic renal scintigraphy; 4 (7%) patients had a renal ultrasound and
34 (58%) had a CT scan performed within 30 days before diuretic renal
scintigraphy. Compared to patients with ≥20% renal function, those
with< 20% renal function were more likely to have renal atrophy on
CT scan (13 [19%] vs. 6 [2%], P < .01).
Predictors of< 20% renal function were evaluated in univariate
and multivariate models (Table 2). After adjusting for potential con-
founders, renal atrophy diagnosed on CT scan (adjusted odds ratio
[aOR] 18.24, 95% conﬁdence interval [CI]= 1.21–274.92) was asso-
ciated with<20% renal function.
We examined the subgroup of women with AKI or elevated creati-
nine and < 20% renal function on diuretic renal scintigraphy who
received a unilateral stent/PCN for their more compromised kidney. Of
the 10 patients in this group, 7 recovered from their AKI/elevated
creatinine and 3 did not. Among the 7 patients who recovered, median
(range) serum creatinine improved from 1.2 (1.08–1.43) mg/dl at AKI/
elevated creatinine diagnosis to 0.82 (0.75–0.90) mg/dl. Based on the
last serum creatinine measurements available at the time of data ac-
quisition, these patients continued to have normal renal function for a
median of 13.1 (0.2–77.4) months. Table 3 describes the renal and
survival outcomes of women in this subgroup.
4. Discussion
In our case series of gynecologic oncology patients with<20%
renal function detected by diuretic renal scintigraphy, the majority of
those who underwent stent or PCN placement recovered from AKI or
elevated creatinine (7 out of 10). Although this conclusion is based on a
small sample size, it suggests that, contrary to reports in the urology
literature (Xu et al., 2017; Ortapamuk et al., 2003), 20% renal function
is not a reliable cutoﬀ for deﬁning kidney salvageability in gynecologic
oncology patients. If this conclusion is conﬁrmed in additional studies,
it has strong implications for our patient population whose treatment
options (e.g., chemotherapy, immunotherapy, radiosensitizing agents)
may depend on maintaining some degree of renal function. A pro-
spective, multicentered study is needed to determine the optimal renal
function threshold for predicting whether or not gynecologic oncology
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patients will beneﬁt from a stent or PCN tube.
Because diuretic renal scintigraphy may not be available to all
gynecologic oncologists, we analyzed predictors of< 20% renal func-
tion in our case series of 353 gynecologic oncology patients who un-
derwent diuretic renal scintigraphy. Renal atrophy on CT scan was a
strong, independent predictor of< 20% function on renal scintigraphy.
Thus, we conservatively recommend that gynecologic oncology patients
with suspected hydronephrosis/hydroureter and no renal atrophy de-
tected on a CT scan can forego diuretic renal scintigraphy and proceed
directly to ureteral stenting/PCN tube placement. However, those with
renal atrophy on CT scan should undergo diuretic renal scintigraphy to
quantify their renal function. Those with renal function over 20%
should undergo ureteral stenting/PCN tube placement. Patients with
renal function< 20% should discuss with their provider the utility of
renal interventions. Such conversations should include the potential
risks of ureteral stent/PCN tube placement (e.g., recurrent infection,
tube dislocation or stent migration, and/or patient discomfort (Lienert
et al., 2009)) and their associated healthcare costs. See Fig. 1 for our
proposed algorithm for the workup for gynecologic oncology patients
with AKI or elevated creatinine and suspected hydronephrosis/hydro-
ureter.
Strengths of this study include its unique focus on diuretic renal
scintigraphy in gynecologic oncology patients. While there is literature
involving management of upper urinary tract obstruction(s) in cancer
patients, there remain gaps in knowledge regarding the impact diuretic
renal scintigraphy can have on tailoring renal interventions and sub-
sequent outcomes including renal function, survival, and quality of life.
Additionally, instead of using surrogate renal function measures such as
CKD or hemodialysis, we used objective renal function data from
diuretic renal scintigraphy. Important weaknesses of our study include
the small sample size drawn from a single institution and the retro-
spective study design, which may have been subject to selection bias.
Thus, our ﬁndings may not be generalizable. Additionally, diuretic
renal scintigraphies were ordered at the providers' discretion and were
rarely repeated after stent or PCN placement to assess recovery of renal
function. Therefore, we could only infer utility of the interventions from
patients' diagnoses of AKI or elevated creatinine. Despite these limita-
tions, the results of our study may help gynecologic oncology patients
and providers decide whether or not to place a ureteral stent(s) or PCN
tube(s).
In conclusion, we have shown that among gynecologic oncology
patients, independent predictors of< 20% renal function include renal
atrophy observed on CT scan. Twenty percent relative renal function on
diuretic renal scintigraphy may not be an appropriate cutoﬀ for kidney
salvageability in gynecologic oncology patients, as the majority of our
patients who underwent ureteral stent/PCN tube placement had im-
proved renal outcomes. Thus, we recommend an individualized ap-
proach for those with severely compromised renal function, including
discussion of potential risks, beneﬁts, and quality of life. Future studies
are warranted to determine optimal renal function cutoﬀs for stent/
PCN tube placement in gynecologic oncology patients.
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Table 1
Demographic and clinicopathologic characteristics.
Characteristic n (%)
Total < 20% Renal
function
≥20% Renal
function
P
N=353 N=58 N=295
Age (years) 57.2
(45.3–66.5)
60.27
(50.1–69.0)
0.07
BMI (kg/m2) 0.44
<30 207 (59) 37 (64) 170 (58)
30–39.9 103 (29) 14 (24) 89 (30)
40–49.9 33 (9) 4 (7) 29 (10)
≥50 10 (3) 3 (5) 7 (2)
Race 0.41
White 260 (74) 45 (77) 215 (73)
Black 84 (24) 13 (22) 71 (24)
Other 8 (2) 0 (0) 8 (3)
Insurance 0.54
Uninsured 33 (9) 6 (10) 27 (9)
Medicare/Medicaid 163 (46) 23 (40) 140 (48)
Private 156 (44) 29 (50) 127 (43)
Tobacco use 0.24
Never 218 (62) 31 (53) 187 (63)
Former 67 (19) 13 (22) 54 (18)
Current 66 (19) 13 (22) 53 (18)
Charleson Comorbidity
Score
6.5 (4.0–8.0) 7 (6.0–8.0) 0.18
Diabetes 57 (16) 9 (15) 48 (16) 0.89
Cardiac disease 181 (51) 30 (52) 151 (51) 0.94
Chronic kidney disease 61 (17) 14 (24) 47 (16) 0.13
Prior abdominal or pelvic
radiation
160 (45) 33 (57) 127 (43) 0.05
Gynecologic cancer type 0.59
Cervical cancer 155 (44) 28 (48) 127 (43)
Endometrial cancer 89 (25) 15 (26) 74 (25)
Ovarian/fallopian/
primary peritoneal
cancer
102 (29) 15 (26) 87 (29)
Vulvar/vaginal cancer 7 (2) 0 (0) 7 (2)
Stage 0.08
I-II 117 (33) 14 (24) 103 (35)
III-IV 206 (58) 40 (69) 166 (56)
Recurrent disease 185 (52) 31 (53) 154 (52) 0.86
Number of chemotherapy
regimens received
0.80
1st line 120 (34) 24 (41) 96 (33)
2nd line 50 (14) 7 (12) 43 (15)
3rd line 32 (9) 5 (9) 27 (9)
>3rd line 35 (10) 6 (10) 29 (10)
Legend: BMI= body mass index; AKI: Acute kidney injury (deﬁned as serum
creatinine increase by 0.3mg/dl in 48 h, or by 1.5-fold in 7 days); Cr:
Creatinine; CT: computed tomography; PCN: percutaneous nephrostomy tube.
Data are median (IQR), or n (%) unless otherwise speciﬁed. Missing values were
included in denominator of the percentages.
Table 2
Predictors of< 20% renal function as detected by diuretic renal scintigraphy.
Risk factor Univariate Multivariate
uOR (95% CI) aOR (95% CI)
Renal atrophy on CT scan 10.78 (3.74–31.10) 18.24 (1.21–274.92)
Prior abdominal or pelvic RT 1.75 (0.99–3.08) 0.86 (0.08–8.82)
AKI 0.27 (0.09–0.77) 0.08 (0.001–4.90)
Legend: CT: computed tomography; RT: radiation therapy; CKD: chronic kidney
disease, AKI: acute kidney injury (deﬁned as serum creatinine increase by
0.3 mg/dl in 48 h, or by 1.5-fold in 7 days); uOR=unadjusted odds ratio;
aOR= adjusted odds ratio; CI= conﬁdence interval.
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